Haemonetics (NYSE:HAE) Reaches New 1-Year High – Here’s What Happened

by · The Markets Daily

Haemonetics Corporation (NYSE:HAE – Get Free Report) reached a new 52-week high during trading on Thursday . The stock traded as high as $87.32 and last traded at $87.1060, with a volume of 1036656 shares traded. The stock had previously closed at $83.84.

Analysts Set New Price Targets

Several equities analysts have issued reports on HAE shares. Weiss Ratings restated a “hold (c-)” rating on shares of Haemonetics in a research note on Monday. Needham & Company LLC increased their price objective on shares of Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, December 6th. BTIG Research reiterated a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research note on Friday, November 21st. Finally, Barrington Research raised their price target on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.70.

Check Out Our Latest Stock Report on Haemonetics

Haemonetics Trading Up 3.9%

The company has a market capitalization of $4.08 billion, a P/E ratio of 25.47, a PEG ratio of 1.58 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The stock has a fifty day moving average of $64.00 and a 200 day moving average of $64.19.

Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter in the prior year, the business posted $1.12 earnings per share. The business’s quarterly revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities research analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Several large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its stake in shares of Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares in the last quarter. River Road Asset Management LLC increased its stake in Haemonetics by 18.7% in the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after buying an additional 260,624 shares in the last quarter. Geode Capital Management LLC raised its holdings in Haemonetics by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after acquiring an additional 23,257 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Haemonetics by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock valued at $53,587,000 after acquiring an additional 26,763 shares in the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Haemonetics by 2.3% in the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after acquiring an additional 24,650 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

(Get Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Further Reading